{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:30:12Z","timestamp":1792024212572,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Opinion Statement<\/jats:title><jats:p>Liver transplantation for hepatocellular carcinoma (HCC) remains an evolving field. Major challenges HCC transplant patients face today include liver organ donor shortages and the need for both better pre-transplant bridging\/downstaging therapies and post-transplant HCC recurrence treatment options. The advent of immunotherapy and the demonstrated efficacy of immune checkpoint inhibitors in multiple solid tumors including advanced\/unresectable HCC hold promise in expanding both the neoadjuvant and adjuvant HCC transplant treatment regimen, though caution is needed with these immune modulating agents leading up to and following transplant. New options for pre-transplant HCC management will expand access to this curative option as well as ensure patients have adequate control of their HCC prior to transplant to maximize the utility of a liver donor. Machine perfusion has been an active area of investigation in recent years and could expand the organ donor pool, helping address current liver donor shortages. Finally, additional HCC biomarkers such as AFP-L3 and DCP have shown promise in improving risk stratification of HCC patients. Together, these three recent advancements will likely alter HCC transplant guidelines in the coming years.<\/jats:p>","DOI":"10.1007\/s11864-024-01247-8","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:02:43Z","timestamp":1722477763000},"page":"1153-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent Advances in Liver Transplantation for Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"P. Jonathan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"1247_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:1\u201328.","journal-title":"Nat Rev Dis Primers"},{"key":"1247_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1247_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u2013700.","journal-title":"N Engl J Med"},{"key":"1247_CR5","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/j.1600-6143.2008.02351.x","volume":"8","author":"FY Yao","year":"2008","unstructured":"Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982\u20139.","journal-title":"Am J Transplant"},{"key":"1247_CR6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394\u2013403.","journal-title":"Hepatology"},{"issue":"6","key":"1247_CR7","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatol. 2023;78(6):1922\u201365.","journal-title":"Hepatol."},{"key":"1247_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver Transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986-994.e3.","journal-title":"Gastroenterology"},{"key":"1247_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/ajt.14549","volume":"18","author":"N Mehta","year":"2018","unstructured":"Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206\u201313.","journal-title":"Am J Transplant"},{"key":"1247_CR10","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/hep.32613","volume":"76","author":"NH Tran","year":"2022","unstructured":"Tran NH, Mu\u00f1oz S, Thompson S, Hallemeier CL, Bruix J. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy. Hepatology. 2022;76:1203.","journal-title":"Hepatology"},{"key":"1247_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000452","author":"N Mehta","year":"2023","unstructured":"Mehta N, Kelley RK, Yao FY. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000452.","journal-title":"Hepatology"},{"key":"1247_CR12","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2016.03.04","author":"WH She","year":"2016","unstructured":"She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.21037\/tgh.2016.03.04.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/hep.22412","volume":"48","author":"FY Yao","year":"2008","unstructured":"Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819\u201327.","journal-title":"Hepatology"},{"key":"1247_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","volume":"161","author":"N Mehta","year":"2021","unstructured":"Mehta N, Frenette C, Tabrizian P, et al. Down-staging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161:1502.","journal-title":"Gastroenterology"},{"key":"1247_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet. 2018;391:1163\u201373.","journal-title":"The Lancet"},{"issue":"23","key":"1247_CR16","first-page":"05115","volume":"S0923\u20137534","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry AB, Trojan J, Meyer T, et al. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2023;S0923\u20137534(23):05115\u201323.","journal-title":"Ann Oncol"},{"key":"1247_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","journal-title":"Lancet Oncol"},{"key":"1247_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. JCO. 2023;41:1434\u201343.","journal-title":"JCO"},{"key":"1247_CR19","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2217\/fon-2019-0097","volume":"15","author":"S Qin","year":"2019","unstructured":"Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019;15:1811\u201322.","journal-title":"Future Oncol"},{"key":"1247_CR20","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1002\/cam4.4090","volume":"10","author":"R Salem","year":"2021","unstructured":"Salem R, Li D, Sommer N, Hernandez S, Verret W, Ding B, Lencioni R. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Med. 2021;10:5437\u201347.","journal-title":"Cancer Med"},{"key":"1247_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"1247_CR22","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1:EVIDoa2100070.","journal-title":"NEJM Evidence"},{"key":"1247_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2:891\u2013903.","journal-title":"Nat Cancer"},{"key":"1247_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:208\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1247_CR25","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/j.annonc.2020.04.429","volume":"31","author":"B Sangro","year":"2020","unstructured":"Sangro B, Kudo M, Qin S, et al. P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1. Ann Oncol. 2020;31:S202\u20133.","journal-title":"Ann Oncol"},{"key":"1247_CR26","unstructured":"Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in emerald-1 phase III trial. 2023. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/imfinzi-combination-improves-pfs-in-liver-cancer.html. Accessed 6 Feb 2024."},{"key":"1247_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS622","author":"AR He","year":"2023","unstructured":"He AR, Toskich B. The ROWAN study: Safety and efficacy of transarterial radioembolization with Y-90 glass microspheres and the STRIDE regimen in hepatocellular carcinoma. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS622.","journal-title":"J Clin Oncol"},{"key":"1247_CR28","unstructured":"RenJi Hospital. Pembrolizumab and LENvatinib in participants with hepatocellular carcinoma (HCC) before liver transplant. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04425226. Accessed 16 Jan 2024."},{"key":"1247_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","volume":"14","author":"S Berhane","year":"2016","unstructured":"Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14:875-886.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1247_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","volume":"23","author":"PJ Johnson","year":"2014","unstructured":"Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev. 2014;23:144\u201353.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1247_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00535-010-0349-7","volume":"46","author":"T Kumada","year":"2011","unstructured":"Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536\u201344.","journal-title":"J Gastroenterol"},{"key":"1247_CR32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cgh.2021.01.043","volume":"20","author":"P Kotwani","year":"2022","unstructured":"Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 are complementary to AFP in predicting high-risk explant features: results of a prospective study. Clin Gastroenterol Hepatol. 2022;20:701-703.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1247_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","volume":"79","author":"JS Norman","year":"2023","unstructured":"Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023;79:1469\u201377.","journal-title":"J Hepatol"},{"key":"1247_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.10.033","volume":"74","author":"N Mehta","year":"2021","unstructured":"Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma \u2013 identifying a threshold that predicts worse post-transplant survival. J Hepatol. 2021;74:829\u201337.","journal-title":"J Hepatol"},{"key":"1247_CR35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/cam4.4538","volume":"11","author":"A Kwong","year":"2022","unstructured":"Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Med. 2022;11:1535\u201341.","journal-title":"Cancer Med"},{"key":"1247_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000149","author":"N Mehta","year":"2023","unstructured":"Mehta N, Kotwani P, Norman J, Shui A, Li P-Y, Saxena V, Chan W, Yao FY. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: results of a prospective study. Liver Transplant. 2023. https:\/\/doi.org\/10.1097\/LVT.0000000000000149.","journal-title":"Liver Transplant"},{"key":"1247_CR37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/lt.24160","volume":"21","author":"ES Orman","year":"2015","unstructured":"Orman ES, Mayorga ME, Wheeler SB, Townsley RM, Toro-Diaz HH, Hayashi PH, Barritt SA. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl. 2015;21:1040\u201350.","journal-title":"Liver Transpl"},{"key":"1247_CR38","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/lt.25819","volume":"26","author":"J Silverstein","year":"2020","unstructured":"Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation after circulatory death is associated with similar posttransplant survival in all but the highest-risk hepatocellular carcinoma patients. Liver Transpl. 2020;26:1100\u201311.","journal-title":"Liver Transpl"},{"key":"1247_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/lt.26029","volume":"27","author":"TG Cotter","year":"2021","unstructured":"Cotter TG, Minhem M, Wang J, Peeraphatdit T, Ayoub F, Pillai A, Hernandez-Alejandro R, di Sabato D, Charlton M. Living-donor liver transplantation in the United States: evolution of frequency, outcomes, center volumes and factors associated with outcomes. Liver Transpl. 2021;27:1019\u201331.","journal-title":"Liver Transpl"},{"key":"1247_CR40","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1111\/j.1600-6143.2012.04272.x","volume":"12","author":"LM Kulik","year":"2012","unstructured":"Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant. 2012;12:2997\u20133007.","journal-title":"Am J Transplant"},{"key":"1247_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/lt.21940","volume":"15","author":"K Vakili","year":"2009","unstructured":"Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl. 2009;15:1861\u20136.","journal-title":"Liver Transpl"},{"key":"1247_CR42","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/TP.0000000000001752","volume":"101","author":"N Mehta","year":"2017","unstructured":"Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time \u201csweet spot.\u201d Transplantation. 2017;101:2071.","journal-title":"Transplantation"},{"key":"1247_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/lt.26439","author":"J Silverstein","year":"2022","unstructured":"Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N. National Experience with Living Donor Liver Transplantation (LDLT) for Hepatocellular Carcinoma (HCC). Liver Transplantation. 2022. https:\/\/doi.org\/10.1002\/lt.26439.","journal-title":"Liver Transplantation"},{"key":"1247_CR44","first-page":"null","volume":"6","author":"P Bhangui","year":"2020","unstructured":"Bhangui P, Yadav S, Soin AS. Post liver transplant recurrence in patients with hepatocellular carcinoma: not necessarily the end of the road! Hepatoma Res. 2020;6:null-null.","journal-title":"Hepatoma Res"},{"key":"1247_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/SLA.0000000000001578","volume":"263","author":"J-H Lee","year":"2016","unstructured":"Lee J-H, Cho Y, Kim HY, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016;263:842\u201350.","journal-title":"Ann Surg"},{"key":"1247_CR46","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/ajt.13875","volume":"16","author":"H Mergental","year":"2016","unstructured":"Mergental H, Perera MTPR, Laing RW, et al. Transplantation of declined liver allografts following normothermic ex-situ evaluation. Am J Transplant. 2016;16:3235\u201345.","journal-title":"Am J Transplant"},{"key":"1247_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41586-018-0047-9","volume":"557","author":"D Nasralla","year":"2018","unstructured":"Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557:50\u20136.","journal-title":"Nature"},{"key":"1247_CR48","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa2031532","volume":"384","author":"R van Rijn","year":"2021","unstructured":"van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation \u2014 a randomized trial. N Engl J Med. 2021;384:1391\u2013401.","journal-title":"N Engl J Med"},{"key":"1247_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/SLA.0000000000004258","volume":"272","author":"M Mueller","year":"2020","unstructured":"Mueller M, Kalisvaart M, O\u2018Rourke J, et al. Hypothermic oxygenated liver perfusion (HOPE) prevents tumor recurrence in liver transplantation from donation after circulatory death. Ann Surg. 2020;272:759.","journal-title":"Ann Surg"},{"key":"1247_CR50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","volume":"3","author":"N Mehta","year":"2017","unstructured":"Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493\u2013500.","journal-title":"JAMA Oncol"},{"key":"1247_CR51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/cancers14030630","volume":"14","author":"MC van Hooff","year":"2022","unstructured":"van Hooff MC, Sonneveld MJ, Ijzermans JN, Doukas M, Sprengers D, Metselaar HJ, den Hoed CM, de Man RA. External validation of the RETREAT score for prediction of hepatocellular carcinoma recurrence after liver transplantation. Cancers (Basel). 2022;14:630.","journal-title":"Cancers (Basel)"},{"key":"1247_CR52","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.hpb.2021.09.008","volume":"24","author":"SHS Reddy","year":"2022","unstructured":"Reddy SHS, Mehta N, Dodge JL, et al. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort. HPB. 2022;24:596\u2013605.","journal-title":"HPB"},{"key":"1247_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/SLA.0000000000001966","volume":"265","author":"KJ Halazun","year":"2017","unstructured":"Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RSJ. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265:557\u201364.","journal-title":"Ann Surg"},{"key":"1247_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/LVT.0000000000000145","volume":"29","author":"BV Tran","year":"2023","unstructured":"Tran BV, Moris D, Markovic D, et al. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium. Liver Transpl. 2023;29:683.","journal-title":"Liver Transpl"},{"key":"1247_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/lt.26332","author":"T Ivanics","year":"2022","unstructured":"Ivanics T, Nelson W, Patel MS, Claasen MPAW, Lau L, Gorgen A, Abreu P, Goldenberg A, Erdman L, Sapisochin G. The Toronto postliver transplantation hepatocellular carcinoma recurrence calculator: a machine learning approach. Liver Transplant. 2022. https:\/\/doi.org\/10.1002\/lt.26332.","journal-title":"Liver Transplant"},{"key":"1247_CR56","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1097\/TXD.0000000000001086","volume":"7","author":"A Aggarwal","year":"2020","unstructured":"Aggarwal A, Te HS, Verna EC, Desai AP. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2020;7:e638.","journal-title":"Transplant Direct"},{"key":"1247_CR57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/TP.0000000000000965","volume":"100","author":"EK Geissler","year":"2016","unstructured":"Geissler EK, Schnitzbauer AA, Z\u00fclke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116\u201325.","journal-title":"Transplantation"},{"key":"1247_CR58","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","volume":"272","author":"AA Schnitzbauer","year":"2020","unstructured":"Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272:855.","journal-title":"Ann Surg"},{"key":"1247_CR59","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","volume":"22","author":"G Sapisochin","year":"2015","unstructured":"Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol. 2015;22:2286\u201394.","journal-title":"Ann Surg Oncol"},{"key":"1247_CR60","doi-asserted-by":"publisher","first-page":"913634","DOI":"10.1155\/2014\/913634","volume":"2014","author":"K Shetty","year":"2014","unstructured":"Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant. 2014;2014:913634.","journal-title":"J Transplant"},{"key":"1247_CR61","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.3390\/cancers15184574","volume":"15","author":"C-H Wassmer","year":"2023","unstructured":"Wassmer C-H, El Hajji S, Papazarkadas X, Compagnon P, Tabrizian P, Lacotte S, Toso C. Immunotherapy and liver transplantation: a narrative review of basic and clinical data. Cancers. 2023;15:4574.","journal-title":"Cancers"},{"key":"1247_CR62","doi-asserted-by":"publisher","first-page":"eadf4287","DOI":"10.1126\/scitranslmed.adf4287","volume":"15","author":"LM Tran","year":"2023","unstructured":"Tran LM, Macedo C, Zahorchak AF, et al. Donor-derived regulatory dendritic cell infusion modulates effector CD8+ T cell and NK cell responses after liver transplantation. Sci Transl Med. 2023;15:eadf4287.","journal-title":"Sci Transl Med"},{"key":"1247_CR63","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/vaccines11081357","volume":"11","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines (Basel). 2023;11:1357.","journal-title":"Vaccines (Basel)"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-024-01247-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:13:37Z","timestamp":1732536817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-024-01247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s11864-024-01247-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"8 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neil Mehta has has received institutional research funding from WAKO Fujifilm Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}